Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bioscience Licenses Electroporation Instruments from Cellectis

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Paris-based Cellectis today said that it has licensed to Harvard Bioscience division Harvard Apparatus exclusive, worldwide rights to manufacture and sell electroporation-based instruments owned by the firm.

Specifically, Harvard Apparatus will have rights to sell the instruments acquired by Cellectis from Cyto Pulse Sciences three months ago for $2.2 million. Among the assets acquired by Cellectis was technology for use with Cellectis' meganuclease platform.

Under terms of the alliance announced today, Harvard Apparatus will pay Cellectis $1.3 million. Cellectis said that it will retain some annual licensing fees owed by existing and new customers. In addition, Cellectis said that it retains all rights to the use of the products for its own research and development programs as well as in clinical trials and prophylactic or therapeutic procedures, for both humans and animals.

The instruments covered by the deal are the DermaVax, OncoVet, Hybrimune, Cyto-LVT-S, and Cyto-LVT-P.

"This license significantly expands the cell biology research product line offered by Harvard Apparatus under the Warner Instruments and BTX brands," Harvard Bioscience CEO Chane Graziano said in a statement. "The technology is quite unique and patent protected and will provide our research customers with new tools to perform their electroporation and electrofusion experiments."

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.